Clinical trials: Retinal Disorders
Age Related Macular Degeneration
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
The purpose of the study is to provide efficacy and safety data for monthly ranibizumab 0.5 mg intravitreal injections in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- EXTEND II (NCT00826371)
- Testing
- ranibizumab 0.5 mg
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
Phase IV, proof-of-concept, randomized, open-label, multi-center, two-arm, 9-month study to evaluate the neuroprotective effects of Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of…
- Trial name
- PRTOECT (NCT00771043)
- Testing
- TYSABRI and AVONEX
- Sponsor
- Biogen
Retinitis Pigmentosa
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
The natural history in individuals with severe retinitis pigmentosa (RP) is variable and there remains an unmet need to better understand disease progression in this population.
- Trial name
- NCT06517940
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sumitomo Pharma America, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study…
- Trial name
- NCT05536297
- Testing
- avacincaptad pegol
- Where
- 117 sites in United States, Argentina and 15 more
- Volunteers
- 278 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Type 1 Diabetes
Diabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.
- Trial name
- DIRECT (NCT00252733)
- Testing
- candesartan cilexetil
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 5,238 people
- Sponsor
- AstraZeneca
Age-related Macular Degeneration
A First-In-Human Study of ARO-033 in Adult Participants
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs) and the safety…
- Trial name
- NCT07662096
- Testing
- ARO-033
- Where
- New Zealand
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- LUNA (NCT06627179)
- Testing
- Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 81 people
- Sponsor
- Laboratoires Thea
Age Related Macular Degeneration
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
- Trial name
- MONET (NCT00713518)
- Testing
- 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
- Where
- 31 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Quark Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch…
- Trial name
- BRAVO (NCT00486018)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 397 people
- Sponsor
- Genentech, Inc.
Healthy, Glaucoma
Clinical Validation Study of RTVue Features
To perform a clinical validation study of RTVue features in volunteers with various ocular pathology or no ocular pathology.
- Trial name
- NCT01370850
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Optovue
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
ROSAH
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
- Trial name
- NCT06395285
- Testing
- DF-003
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
Retinal Detachment
A Study in Subjects With Retinal Detachment
The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).
- Trial name
- NCT00210067
- Testing
- denufosol tetrasodium (INS37217) Intravitreal Injection
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Retinal Disorder
Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease
To evaluate the efficacy of ZA oral solution in subjects with IRD caused by biallelic recessive RPE65 or LRAT gene mutations and phenotypically diagnosed as Leber's Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP).
- Trial name
- NCT04311112
- Testing
- ZA Low dose, ZA high dose
- Where
- United States
- Sponsor
- Retinagenix Holdings
Retinitis Pigmentosa
Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period.
- Trial name
- NCT01786395
- Testing
- UF-021
- Where
- 34 sites in Japan
- Volunteers
- 202 people
- Sponsor
- R-Tech Ueno, Ltd.
Geographic Atrophy of the Macula, Macular Degeneration
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
- Trial name
- SIGLEC (NCT05839041)
- Testing
- AVD-104, Avacincaptad
- Where
- 56 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aviceda Therapeutics, Inc.
Early Age Related Macular Degeneration (Disorder)
Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes
The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.
- Trial name
- NCT04776031
- Testing
- R:GEN Laser System
- Where
- Australia
- Volunteers
- 31 people
- Sponsor
- Lutronic Vision, Inc
Glaucoma, Retinal Disease
Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100
This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.
- Conditions
- Glaucoma, Retinal Disease, Healthy
- Trial name
- OCT (NCT03505567)
- Testing
- KOWA OCT Bi-µ, Optovue iVue 100
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.